MNG112
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.268
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.258
- OXIDATIVE_PHOSPHORYLATION+0.242
- ADIPOGENESIS+0.227
- COAGULATION+0.226
- PEROXISOME+0.217
- KRAS_SIGNALING_DN+0.215
- XENOBIOTIC_METABOLISM+0.193
- UV_RESPONSE_UP+0.165
- WNT_BETA_CATENIN_SIGNALING+0.153
Top 10 suppressed
- G2M_CHECKPOINT-0.355
- E2F_TARGETS-0.317
- MITOTIC_SPINDLE-0.204
- PROTEIN_SECRETION-0.172
- ANGIOGENESIS-0.168
- UV_RESPONSE_DN-0.165
- MTORC1_SIGNALING-0.111
- PI3K_AKT_MTOR_SIGNALING-0.088
- KRAS_SIGNALING_UP-0.086
- NOTCH_SIGNALING-0.079
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG610 | — | — | 0.760 |
| 2 | 131e315e-6653-4199-b653-42b81644dad9 | — | — | 0.750 |
| 3 | MNG1262 | — | — | 0.727 |
| 4 | b83a1cf6-50a6-44fa-834d-8b3df88149fa | — | — | 0.705 |
| 5 | MNG1090 | — | — | 0.701 |
| 6 | SRR23303751 | — | — | 0.698 |
| 7 | SRR25043613 | — | — | 0.691 |
| 8 | 9c8140ab-454c-4f62-aa6e-d1cfe4e498e0 | — | — | 0.688 |
| 9 | SRR9879284 | — | cohortA1 | 0.683 |
| 10 | SAMN03290901 | — | — | 0.677 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.268 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.258 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.242 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.227 | Inavolisib | — uncovered |
| COAGULATION | 0.226 | Binimetinib | — uncovered |
| PEROXISOME | 0.217 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.215 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.193 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.165 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.153 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.147 | Idelalisib | — uncovered |
| COMPLEMENT | 0.146 | Inavolisib | — uncovered |
| APOPTOSIS | 0.139 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.114 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.113 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.106 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.097 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.094 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.091 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.087 | Inavolisib | — uncovered |